ImmuCell Corp. (ICCC)
9.75
+0.15
(+1.56%)
USD |
NASDAQ |
Oct 02, 16:00
ImmuCell Enterprise Value : 92.14M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 92.14M |
| October 01, 2026 | 90.78M |
| September 30, 2026 | 92.59M |
| September 29, 2026 | 93.86M |
| September 28, 2026 | 93.32M |
| September 25, 2026 | 93.73M |
| September 24, 2026 | 94.14M |
| September 23, 2026 | 94.32M |
| September 22, 2026 | 94.32M |
| September 21, 2026 | 95.59M |
| September 18, 2026 | 93.96M |
| September 17, 2026 | 94.23M |
| September 16, 2026 | 90.87M |
| September 15, 2026 | 90.59M |
| September 14, 2026 | 91.78M |
| September 11, 2026 | 93.05M |
| September 10, 2026 | 93.64M |
| September 09, 2026 | 93.59M |
| September 08, 2026 | 92.96M |
| September 04, 2026 | 93.50M |
| September 03, 2026 | 94.41M |
| September 02, 2026 | 94.41M |
| September 01, 2026 | 93.68M |
| August 31, 2026 | 92.50M |
| August 28, 2026 | 93.86M |
| Date | Value |
|---|---|
| August 27, 2026 | 94.59M |
| August 26, 2026 | 94.59M |
| August 25, 2026 | 92.96M |
| August 24, 2026 | 92.96M |
| August 21, 2026 | 94.95M |
| August 20, 2026 | 95.23M |
| August 19, 2026 | 95.59M |
| August 18, 2026 | 92.23M |
| August 17, 2026 | 91.68M |
| August 14, 2026 | 94.86M |
| August 13, 2026 | 102.58M |
| August 12, 2026 | 103.31M |
| August 11, 2026 | 103.04M |
| August 10, 2026 | 103.22M |
| August 07, 2026 | 103.49M |
| August 06, 2026 | 103.67M |
| August 05, 2026 | 101.22M |
| August 04, 2026 | 104.13M |
| August 03, 2026 | 103.85M |
| July 31, 2026 | 105.40M |
| July 30, 2026 | 104.04M |
| July 29, 2026 | 103.58M |
| July 28, 2026 | 105.67M |
| July 27, 2026 | 104.67M |
| July 24, 2026 | 103.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
| Biogen, Inc. | 39.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.835M |
| Revenue (Quarterly) | 7.186M |
| Total Expenses (Quarterly) | 5.352M |
| EPS Diluted (Quarterly) | 0.1996 |
| Gross Profit Margin (Quarterly) | 33.92% |
| Profit Margin (Quarterly) | 25.53% |
| Earnings Yield | 0.86% |
| Operating Earnings Yield | 2.11% |
| Normalized Earnings Yield | 1.414 |